Poteligeo 20 MG/5 ML vial 5ML
Ended Awarded
- Contract number
- SPE2DB25FYX31
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $41,246
Award facts
- Contract value 100% obligated
- $41,246.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $41,246.04 by the Defense Logistics Agency (DLA) on August 14, 2025. The delivery order covers the supply of Poteligeo (mogamulizumab) 20 mg/5 ml vials, an oncology pharmaceutical product used in the treatment of certain cutaneous T-cell lymphomas. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of September 5, 2025, and no set-aside designation was utilized. This award represents an individual transaction under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA, valued at $499,999,999 and valid through November 2026, which authorizes the agency to issue delivery orders for a comprehensive range of pharmaceutical products supporting military health facilities worldwide.
The DLA's pharmaceutical supply chain relies on vendors like DMS Pharmaceutical Group to distribute branded and generic prescription drugs, biologics, and specialized medical products to Department of Defense healthcare facilities. This particular delivery order for Poteligeo exemplifies the company's role in supplying oncology treatments and other specialty medications critical to military medical operations. DMS Pharmaceutical Group's consistent success in securing federal pharmaceutical contracts without set-aside designations demonstrates its competitive positioning in the federal procurement market, supported by its woman-owned small business status and established presence in government contracting since 2001.
Quick answers
Who was awarded contract SPE2DB25FYX31?
SPE2DB25FYX31 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 14, 2025.
How much is contract SPE2DB25FYX31 worth?
The government has obligated $41,246 on SPE2DB25FYX31.
Is contract SPE2DB25FYX31 an order under another contract?
Yes. SPE2DB25FYX31 is a delivery order under SPE2DB22D9133, an indefinite delivery contract.
Was contract SPE2DB25FYX31 competed?
The extent of competition for SPE2DB25FYX31 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award